Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.36 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.36 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.36 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.36 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.36 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.36 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 0.36 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3048397 | 0.88 | PPARA (0.46) | EPHX2CYP1A2CYP2C19CYP2C9ALDH1A1 | |
| SCHEMBL3045255 | 0.87 | PPARA (0.45) | EPHX2CYP1A2CYP2C19CYP2C9ALDH1A1 | |
| SCHEMBL3045251 | 0.87 | PPARA (0.45) | EPHX2CYP1A2CYP2C19CYP2C9ALDH1A1 | |
| SCHEMBL3050029 | 0.74 | IKBKB (0.37) | EPHX2ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL3048782 | 0.72 | PPARA (0.49) | CYP1A2CYP2C19CYP2C9ALDH1A1NPC1 | |
| SCHEMBL3048817 | 0.70 | PTPN1 (0.44) | CYP1A2CYP2C19CYP2C9ALDH1A1NPC1 | |
| SCHEMBL3051685 | 0.67 | CYP4F2 (0.46) | CYP1A2CYP2C19CYP2C9ALDH1A1NPC1 | |
| SCHEMBL3052260 | 0.66 | HDAC1 (0.50) | EPHX2NOTUMSLC9A1 | |
| SCHEMBL4629766 | 0.65 | NOTUM (0.48) | EPHX2CYP1A2CYP2C19CYP2C9ALDH1A1 | |
| SCHEMBL3048406 | 0.65 | PTPN1 (0.52) | CYP1A2CYP2C19CYP2C9ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765796-B2 | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP-1) compound or a melanocortin-4 receptor (MC4) agonist peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140031287-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MIC4) AGONIST PEPTIDE | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8552039-B2 | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP-1) compound or a melanocortin-4 receptor (MC4) agonist peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20100120876-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MC4) AGONIST PEPTIDE | EMISPHERE TECHNOLOGIES, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-7662771-B2 | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP)-1 compound or a melanocortin-4 receptor (MC4) agonist peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20080214448-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | EMISPHERE TECHNOLOGIES INC. (US) | 2008-09-04 | — | — | US | disclosed |
| EP-1658273-B1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | LILLY CO ELI (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1658273-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | ELI LILLY AND COMPANY (US) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005019184-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120876-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MC4) AGONIST PEPTIDE | MC4R, GLP1R, MC3R | GABRP 1425/4885GABRD 2059/4885GABRA1 1063/4885 |
| US-20080214448-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | MC4R, GLP1R, MC3R | GABRP 1457/4885GABRD 2149/4885GABRA1 1089/4885 |
| US-20140031287-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MIC4) AGONIST PEPTIDE | MC4R, GLP1R, MC3R | GABRP 1349/4885GABRD 1540/4885GABRA1 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.